Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 11:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity

LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced a new publication in the journal Neuromodulation: Technology at the...
October 22, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
October 09, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and...
October 07, 2025 16:05 ET | Source: Neurona Therapeutics

Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)

Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)
October 03, 2025 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by...
September 29, 2025 08:00 ET | Source: Neura Health

Neura Health Secures $11.4 Million Series A to Fuel National Expansion of Comprehensive, Tech-Enabled Neurology Care Model

Neura Health Secures $11.4M Series A led by American Heart Association's Go Red for Women Venture Fund to expand tech-enabled neurology care model.
September 22, 2025 11:02 ET | Source: Angelini Pharma

Angelini Pharma sigla un accordo di opzione esclusiva con Sovargen per ottenere i diritti globali di sviluppo e commercializzazione di un asset innovativo nell'ambito della salute del cervello

Angelini Pharma ottiene un'opzione esclusiva per acquisire i diritti globali di sviluppo e commercializzazione al di fuori della Repubblica di Corea, della Cina, di Hong Kong, di Macao e Taiwan di...
September 22, 2025 11:02 ET | Source: Angelini Pharma

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Ass
$European Refractory Epilepsy Treatment Market$

September 16, 2025 06:43 ET | Source: Research and Markets

Europe Refractory Epilepsy Treatment Research Report 2025 | Market to More Than Double to Reach $2.82 Billion by 2035, Driven by CBD Growth, Uptake of Neuromodulation Therapies, Strong R&D Pipeline

Dublin, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The "Europe Refractory Epilepsy Treatment Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The Europe...
$Asia-Pacific Refractory Epilepsy Treatment Market$

September 16, 2025 06:25 ET | Source: Research and Markets

Asia-Pacific Refractory Epilepsy Treatment Market Research 2025 | Market to Reach $2.48 Billion by 2035 - Opportunities Fueled by a Shift from Neo-Adjuvant Approaches Driven by Diagnostic Advancements

Dublin, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Refractory Epilepsy Treatment Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The...